Sanofi (SNY)

NASDAQ: SNY · Real-Time Price · USD
47.03
-0.62 (-1.30%)
At close: Sep 12, 2025, 4:00 PM EDT
47.34
+0.31 (0.66%)
After-hours: Sep 12, 2025, 7:51 PM EDT
-1.30%
Market Cap115.08B
Revenue (ttm)53.71B
Net Income (ttm)10.72B
Shares Out 1.22B
EPS (ttm)8.65
PE Ratio10.74
Forward PE9.91
Dividend$1.60 (3.40%)
Ex-Dividend DateMay 9, 2025
Volume2,728,104
Open47.38
Previous Close47.65
Day's Range47.01 - 47.68
52-Week Range44.73 - 60.12
Beta0.44
AnalystsBuy
Price Target61.50 (+30.77%)
Earnings DateOct 24, 2025

About SNY

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange NASDAQ
Ticker Symbol SNY
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial numbers in EUR Financial Statements

Analyst Summary

According to 4 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $61.5, which is an increase of 30.77% from the latest price.

Price Target
$61.5
(30.77% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t...

4 days ago - GlobeNewsWire

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...

4 days ago - Reuters

Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®

Mandy Moore joins Elaine Welteroth, Gaby Dalkin, Katya Echazarreta, and Shawn Johnson East to share their personal respiratory syncytial virus (RSV) stories and why they chose BEYFORTUS to help protec...

4 days ago - PRNewsWire

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

5 days ago - GlobeNewsWire

Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sanofi (NASDAQ:SNY) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Paul Hudson - CEO & Director Conference Call Participants Sarita Kapila ...

5 days ago - Seeking Alpha

Sanofi market value tanks following weak results on eczema drug trials

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab...

10 days ago - Fast Company

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fre...

10 days ago - Benzinga

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA SNY stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expecta...

10 days ago - Benzinga

Sanofi Shares Sink as Experimental Drug Results Disappoint

Sanofi shares plunged at the market open Thursday as results from a late-stage trial of its experimental drug to treat skin conditions disappointed investors.

10 days ago - Market Watch

Sanofi shares sink over 9% on weak trial results for experimental inflammation drug

Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its experimental inflammatory disease drug amlitelimab fell short of Wall Street expectations.

10 days ago - Reuters

Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial

Amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and adults with atopic dermatitis.

11 days ago - WSJ

Press Release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

11 days ago - GlobeNewsWire

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

11 days ago - Reuters

Now Is The Time To Buy This High-Yielding Trio

The focus of today will be on CMCSA, AES, and SNY. The trifecta provides a reasonably secure 4.5% average yield, an A- average S&P credit rating, and is 33% undervalued. Comcast Corporation could be s...

Other symbols: AESCMCSA
15 days ago - Seeking Alpha

US FDA approves Sanofi's drug for a rare blood disorder

The U.S. Food and Drug Administration has approved Sanofi's drug to treat a type of blood disorder, the company said on Friday, in a sign that the French drugmaker's $3.7 billion bet on the treatment ...

16 days ago - Reuters

Press Release: Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia

Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA...

16 days ago - GlobeNewsWire

Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease

Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...

4 weeks ago - GlobeNewsWire

Sanofi stops supply of high cholesterol drug to China due to limited availability

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to lim...

4 weeks ago - Reuters

Sanofi: Playing To Win

Sanofi's strategic pivot to immunology and rare diseases, plus AI-driven R&D, targets higher margins and sustainable long-term growth. Blockbuster drugs like Dupixent, Altuviiio, and Beyfortus, alongs...

5 weeks ago - Seeking Alpha

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”).

5 weeks ago - GlobeNewsWire

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

6 weeks ago - WSJ

European drugmakers fall after Trump raises stakes over US drug price cuts

Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...

Other symbols: AZNMRKNVO
6 weeks ago - Reuters

Sanofi (SNY) Q2 2025 Earnings Call Transcript

Sanofi (NASDAQ:SNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care François-Xavier Roger - Executive VP & CFO Houma...

6 weeks ago - Seeking Alpha

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...

6 weeks ago - Forbes

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.

6 weeks ago - CNBC Television